An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor

Daniel Zaidman; Paul Gehrtz; Mihajlo Filep; Daren Fearon; Jaime Prilusky; Shirly Duberstein; Galit Cohen; David Owen; Efrat Resnick; Claire Strain-Damerell; Petra Lukacik; Covid-Moonshot Consortium; Haim Barr; Martin A. Walsh; Frank von Delft; Nir London

doi:10.1101/2020.09.21.299776

New Results

An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 M^pro inhibitor

Daniel Zaidman, Paul Gehrtz, Mihajlo Filep, Daren Fearon, Jaime Prilusky, Shirly Duberstein, Galit Cohen, David Owen, Efrat Resnick, Claire Strain-Damerell, Petra Lukacik, Covid-Moonshot Consortium, Haim Barr, Martin A. Walsh, View ORCID ProfileFrank von Delft, View ORCID ProfileNir London

doi: https://doi.org/10.1101/2020.09.21.299776

Daniel Zaidman

1Dept. of Organic Chemistry, Weizmann Institute of Science, 7610001, Rehovot, Israel

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Paul Gehrtz

1Dept. of Organic Chemistry, Weizmann Institute of Science, 7610001, Rehovot, Israel

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mihajlo Filep

1Dept. of Organic Chemistry, Weizmann Institute of Science, 7610001, Rehovot, Israel

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Daren Fearon

2Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot OX11 0QX, U.K

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jaime Prilusky

3Life Sciences Core Facilities, Weizmann Institute of Science, 7610001, Rehovot, Israel

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shirly Duberstein

4Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, The Weizmann Institute of Science, Rehovot, 7610001, Israel

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Galit Cohen

4Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, The Weizmann Institute of Science, Rehovot, 7610001, Israel

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David Owen

2Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot OX11 0QX, U.K

5Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, U.K

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Efrat Resnick

1Dept. of Organic Chemistry, Weizmann Institute of Science, 7610001, Rehovot, Israel

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Claire Strain-Damerell

2Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot OX11 0QX, U.K

5Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, U.K

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Petra Lukacik

2Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot OX11 0QX, U.K

5Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, U.K

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Haim Barr

4Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, The Weizmann Institute of Science, Rehovot, 7610001, Israel

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martin A. Walsh

2Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot OX11 0QX, U.K

5Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, U.K

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Frank von Delft

2Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot OX11 0QX, U.K

5Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, U.K

6Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Headington, OX3 7DQ, UK

7Department of Biochemistry, University of Johannesburg, Auckland Park 2006, South Africa

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Frank von Delft

Nir London

1Dept. of Organic Chemistry, Weizmann Institute of Science, 7610001, Rehovot, Israel

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Nir London
For correspondence: nir.london@weizmann.ac.il

Abstract
Full Text
Info/History
Metrics
Supplementary material
Data/Code
Preview PDF

List of the Moonshot Consortium members[supplements/299776_file03.xlsx]
Supp. Dataset 1[supplements/299776_file04.xlsx]
Supplementary Material[supplements/299776_file05.pdf]
Supplementary Chemical Information[supplements/299776_file06.pdf]

View the discussion thread.

PreviousNext

Posted September 22, 2020.

Download PDF

Supplementary Material

Data/Code

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor

Message Subject (Your Name) has forwarded a page to you from bioRxiv

Message Body (Your Name) thought you would like to see this page from the bioRxiv website.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 M^pro inhibitor

bioRxiv 2020.09.21.299776; doi: https://doi.org/10.1101/2020.09.21.299776

Share This Article:

Citation Tools

An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 M^pro inhibitor

bioRxiv 2020.09.21.299776; doi: https://doi.org/10.1101/2020.09.21.299776

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Tweet Widget
Facebook Like
Google Plus One

Subject Area

Biochemistry

Subject Areas

All Articles

Animal Behavior and Cognition (4672)
Biochemistry (10340)
Bioengineering (7658)
Bioinformatics (26300)
Biophysics (13501)
Cancer Biology (10672)
Cell Biology (15413)
Clinical Trials (138)
Developmental Biology (8487)
Ecology (12806)
Epidemiology (2067)
Evolutionary Biology (16831)
Genetics (11382)
Genomics (15469)
Immunology (10603)
Microbiology (25182)
Molecular Biology (10210)
Neuroscience (54383)
Paleontology (399)
Pathology (1667)
Pharmacology and Toxicology (2889)
Physiology (4334)
Plant Biology (9235)
Scientific Communication and Education (1586)
Synthetic Biology (2555)
Systems Biology (6773)
Zoology (1461)